BioSpace

The untapped potential of drug repurposing

In this episode of Denatured, you'll hear from Daniel Tillett, CEO of Racura Oncology and Sten Sörensen, CEO of Cereno Scientific. We explore why the FDA is now prioritizing drug repurposing, and what it will take to turn existing molecules into viable new therapies.

By BioSpace

1 min read
The untapped potential of drug repurposing
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights